Next generation antibody therapeutics

Crescendo Biologics aims to create a pipeline of novel medicines based on its proprietary class-leading antibody fragment platform.

Crescendo is developing a unique transgenic mouse platform to rapidly and predictably generate high-affinity human heavy chain-only antibodies. These will be used to produce small antibody fragments (“VH fragments”) that have no requirement for humanisation and will form the basis of novel therapeutics with significant advantages over existing antibody therapeutics.

 

Image kindly supplied by BBT

---